[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"crs---cytokine-release-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:crs---cytokine-release-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100545066","early-detection-of-complications-during-immunotherapy-for-haematological-malignancy-100545066",false,"NCT06377059","Early Detection of Complications During Immunotherapy for Haematological Malignancy","Early Detection of Complications During Immunotherapy for Haematological Malignancy - Description of Associated Vital Signs and Immune Responses","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients diagnosed with haematologic malignant disease (e.g. malignant lymphoma)\n* Patients scheduled for treatment with CART or BsAbs\n\nExclusion Criteria:\n\n* Patient is pregnant\n* Patient has a pacemaker\n* Patient is allergic to one or more of the materials that the equipment consists of\n* Investigator deems patient not able to comply with participation in the study","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","Aims\n\n* To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications\n* Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on a combination of physiological and immunological parameters can contribute to early detection of patients at risk for clinical complications after anti-cancer treatment.",[26,27],"Hematologic Cancer","CRS - Cytokine Release Syndrome",[29],"wireless monitoring","RECRUITING","2026-05-12",{"date":33,"type":34},"2026-05-15","ACTUAL",{"date":36,"type":34},"2024-12-02",{"date":38,"type":20},"2027-07-01",{"name":40,"class":41},"Rigshospitalet, Denmark","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100462776","early-phase-1-tadekinig-alfa-il-18bp-rescue-therapy-for-car-t-cell-related-cytokine-release-syndrome-crs-and-hlh-like-syndrome-100462776","NCT05306080","Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome","Pilot, Open-Label Study Evaluating the Safety and Feasibility of Using Rescue Therapies for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome","Inclusion Criteria:\n\n1. Signed, written informed consent\n2. Male or female patients age ≥ 18 years\n3. Have been co-enrolled in a University of Pennsylvania-Sponsored, CCI-Initiated CAR T cell clinical trial.\n4. Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol\n\nExclusion Criteria:\n\n1. Pregnant or nursing (lactating) women.\n2. Known hypersensitivity to the active substance or one of the excipients of the investigational product(s).",{"count":51,"type":20},10,[53],"EARLY_PHASE1","This is a pilot, open-label study to assess the safety and feasibility of using investigational drug(s) as rescue therapies for CAR T cell related CRS and HLH-like syndrome (CRHLS).",[27,56],"HLH","2026-02-27",{"date":59,"type":34},"2026-03-03",{"date":61,"type":34},"2022-04-17",{"date":63,"type":20},"2028-04",{"name":65,"class":41},"University of Pennsylvania",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":42},"100601144","phase-2-a-phase-ii-study-of-siltuximab-for-crsicans-after-car-t-in-multiple-myeloma-100601144","NCT07106671","A Phase II Study of Siltuximab for CRS\u002FICANs After CAR-T in Multiple Myeloma","A Prospective, Single-Arm, Single-Center, Phase II Clinical Trial of Siltuximab for Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity After CAR-T Treatment in Multiple Myeloma","Inclusion Criteria:\n\n1. Be informed and voluntarily sign the Informed Consent Form (ICF).\n2. Age ≥18 years old.\n3. Diagnosed with multiple myeloma according to IMWG diagnostic criteria.\n4. Developed CRS (grade ≥1) and\u002For ICANS (grade ≥1) after CAR-T treatment.\n\nExclusion Criteria:\n\n1. Creatinine clearance \\\u003C30 mL\u002Fmin.\n2. Platelet count \\\u003C75,000\u002FμL, absolute neutrophil count \\\u003C1,000\u002FμL, or hemoglobin \\\u003C60 g\u002FL at screening.\n3. ALT or AST \\>3× ULN, or bilirubin \\>2× ULN.\n4. Known severe cardiac conditions, including NYHA class III\u002FIV heart failure, uncontrolled angina, arrhythmia, or hypertension, myocardial infarction within 6 months, or other uncontrolled\u002Fsevere cardiovascular diseases, including prior cerebrovascular events with residual deficits.\n5. Severe comorbidities, including active infections, known active HBV\u002FHCV, HIV infection, uncontrolled diabetes, or serious conditions like chronic restrictive lung disease or cirrhosis.\n6. Known intolerance to Siltuximab.\n7. Known central nervous system (CNS) involement.",{"count":74,"type":20},20,[76],"PHASE2","This is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.",[27,79],"Myeloma","2025-07-30",{"date":82,"type":34},"2025-08-06",{"date":84,"type":20},"2025-08-10",{"date":86,"type":20},"2027-08-01",{"name":88,"class":41},"Institute of Hematology & Blood Diseases Hospital, China"]